< formatted article >

White House Strikes New Deal with Regeneron to Tame Sky-High Drug Prices

The Biden administration is set to unveil a landmark pricing agreement with Regeneron Pharmaceuticals, a move that could reshape how some of the most expensive drugs in the U.S. are priced—starting with their Covid-19 antibody treatments.

A Rare Collaboration in a Broken System

Regeneron, the maker of monoclonal antibody therapies like REGEN-COV, remained tight-lipped as markets reacted with optimism—its stock surged over 2% at the opening bell. But behind the numbers lies a bigger question: Can voluntary deals truly curb America’s runaway drug costs?

The White House’s push comes as part of a broader initiative to slash pharmaceutical prices, which are among the highest globally. Yet, despite invitations extended to multiple drugmakers, only a handful—including Regeneron—have agreed to negotiate. Critics argue that without mandatory participation, such deals risk becoming little more than symbolic gestures.

Will This Be Enough?

Progressives demand bolder action, arguing that voluntary price cuts won’t fix a system rigged in favor of Big Pharma. Others see this as a cautious first step—one that could pave the way for more sweeping reforms if successful.

One thing is clear: the outcome of this deal will set a precedent. If Regeneron’s cooperation yields tangible savings, other pharmaceutical giants may find themselves under renewed pressure to follow suit—or face tougher government intervention.

The Clock Is Ticking

With healthcare costs straining household budgets and political pressure mounting, the administration is betting on this strategy to deliver quick wins. But in a $500 billion industry, even the most well-intentioned deals may struggle to move the needle—unless more players join the table.

Stay tuned. This story is far from over.